Oncology Articles | Page 2

Triplet Regimen Shows Durable Responses in BRAF V600E-Mutant Metastatic CRC
Clinical outcomes with the combination of encorafenib, binimetinib, and cetuximab exceed historic data in patients with BRAF V600E-mutant metastatic colorectal cancer.
Antiangiogenics, ADCs Still Have Roles in Ovarian Cancer Treatment
For all the positive data associated with PARP inhibitors in patients with epithelial ovarian cancer who have known BRCA mutations and despite several agents winning FDA approval over the past few years, PARP inhibitors aren’t curing patients.
Regorafenib Extends PFS in Locally Advanced Biliary Tract Cancer
The oral multi-kinase inhibitor regorafenib extended progression-free survival in patients with metastatic or unresectable biliary tract cancer who were previously treated with gemcitabine and a platinum-based chemotherapy. 
Westin Highlights the Evolving Role of PARP Inhibitors in Ovarian Cancer
Shannon Westin, MD, discusses the evolving role of PARP inhibitors in ovarian cancer, novel investigational agents, and the importance of molecular testing.
Dabrafenib/Trametinib Combo Induces High Responses in BRAF V600E-Mutant Biliary Tract Cancer
The combination of dabrafenib and trametinib induced responses in nearly half of patients with BRAF V600E–mutated biliary tract cancer who participated in a phase II basket trial that enrolled patients with BRAF V600E–mutated rare cancers.
SM-88 Achieves Encouraging Clinical Benefit Rate in Metastatic Pancreatic Cancer
The novel oral anticancer regimen known as SM-88, which consists of a tyrosine derivative, an mTOR inhibitor, a CYP3a4 inducer, and an oxidative stress catalyst, has promising efficacy with no meaningful toxicity in patients with metastatic pancreatic cancer who have progressed on at least 1 prior line of therapy.
Investigators Still Seeking Options Beyond PARP Inhibitors in Ovarian Cancer
Targeted therapy is effectively established as an option for patients with ovarian cancers. However, beyond PARP inhibition in the BRCA-mutated or homologous recombination deficient population, questions remain about how to best treat these patients.
Immunotherapy Agents Could Improve Survival in Advanced Cervical Cancer
The prognosis for women with recurrent or metastatic cervical cancer after treatment failure is notoriously poor, but immunotherapy agents may offer longer survival for this population.
Analysis Sustains TAS-102 Survival Benefit in Gastric Cancer
Overall survival in metastatic gastric/gastroesophageal junction cancer improved significantly in patients who received the combination therapy TAS-102, irrespective of prior gastrectomy.
FDA Approves Third Trastuzumab Biosimilar
The FDA has granted an approval to SB3 (Ontruzant; trastuzumab-dttb), a trastuzumab biosimilar, for the treatment of patients with HER2-overexpressing breast cancer or metastatic gastric or gastroesophageal junction adenocarcinoma.
Publication Bottom Border
Border Publication